OKUR: onkuretherapeutics.com Company Value to Net Income

OnKure Therapeutics - graphic logo of issuer OKUR

The exclusivity of OnKure Therapeutics Inc (OKUR) developments is guaranteed by strict FDA regulations and patent protection of molecules. The company's high authority within the scientific community is based on the creation of drugs for targeted action on genetic tumor malfunctions. The market valuation dynamics of the asset, where the P/E stands at -1.70, confirm the success of the strategy to create synergy with biopharmaceutical centers for the development of precision inhibitors.

Price to Earnings Ratio: OnKure (OKUR) for 10/08/2024 - 11/18/2026

Comprehensive metric breakdowns and analytics for OnKure Therapeutics, Inc. (OKUR)

Comprehensive company analysis:OKUR (OnKure Therapeutics, Inc.)
Flagship merchandise of OnKure Therapeutics

When screening issuer reliability, it is essential to analyze the P/E ratio as the relationship between market capitalization and net income, which determines the cost of one dollar of earnings. Amid geopolitical barriers and clinical trial disruptions for OnKure Therapeutics Inc (OKUR), this price-to-earnings chart clearly demonstrates the market's willingness to pay a premium for future innovations, despite the slowdown in oncology drug development and logistical risks.

Analysis of competing companies

ONC: Company Value to Net Income|Price to Earnings Ratio HALO (Halozyme Inc.)|RVMD (RevMed) - Company Value to Net Income|P/E Multiple AAPG (ascentage.com)|CGON - Price to Earnings Ratio|URGN: Price to Earnings Ratio|BCAX - P/E Multiple|Personalis Corp (PSNL) - Price to Earnings Ratio|Erasca Corp - Company Value to Net Income|DCTH (Delcath Systems Inc) - P/E Multiple|Market Cap to Earnings Y-mAbs Therapeutics, Inc. YMAB|P/E Multiple AURA|Price to Earnings Ratio Candel Therapeutics, Inc. CADL|P/E Multiple ARAY (Accuray, Inc.)|SELLAS Life Sciences - Price to Earnings Ratio|ACTU: Price to Earnings Ratio|Citius Oncology, Inc. - Market Price to Net Income Ratio|HURA (TuHURA Biosciences) - Price to Earnings Ratio|TARA: Market Price to Net Income Ratio|Price to Earnings Ratio FATE|WHWK: Company Value to Net Income|Price to Earnings Ratio TCRX (TScan Therapeutics Inc)|Business Payback Period Champions Oncology Inc|P/E Multiple XBIT (XBiotech Inc.)|Company Value to Net Income CVM|OS Therapies Inc. - P/E Multiple|RADX - P/E Multiple|ARTV: P/E Multiple|ANL: Market Price to Net Income Ratio|Price to Earnings Ratio VERU|TPST: Company Value to Net Income|Price to Earnings Ratio xiliotx.com (XLO)|Renovaro - Price to Earnings Multiple|Price to Earnings Ratio Mural Oncology MURA|KAPA - Price to Earnings Ratio|CytoMed Therapeutics - P/E Multiple|Business Payback Period Curis CRIS|APLM: P/E Multiple|Price to Earnings Ratio Tharimmune, Inc.|ADVB (Advanced Biomed) - P/E Multiple|Genprex - Market Cap to Net Income|Price to Earnings Ratio calidibio.com (CLDI)|SBFM (Sunshine Biopharma Inc.) - Company Value to Net Income|P/E Multiple XBIO (Xenetic Biosciences)|Salarius Pharmaceuticals (SLRX) - Market Cap to Earnings|PPBT: Price to Earnings Ratio|Company Value to Net Income AONC (American Oncology Network, Inc.)|BeOne Medicines (BGNE) - Price to Earnings Ratio|Checkpoint Therapeutics, Inc (CKPT) - P/E Multiple|Price to Earnings Ratio Elevation Oncology, Inc.|ICAD: Company Value to Net Income|Price to Earnings Ratio ikenaoncology.com (IKNA)|Price to Earnings Ratio NTBL (Notable Labs, Ltd.)|P/E Multiple VIRX (viracta.com)|MOR - Price to Earnings Ratio|NAYA - Price to Earnings Ratio|Market Cap to Net Income AAPGV